{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:45:06Z","timestamp":1773020706196,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"the Ministry of Education, Science and Technological Development of the Republic of Serbia","award":["175007"],"award-info":[{"award-number":["175007"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2023,4,3]]},"DOI":"10.1080\/13543784.2023.2193680","type":"journal-article","created":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T07:58:05Z","timestamp":1679126285000},"page":"325-331","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Investigational new drugs for the treatment of Dravet syndrome: an update"],"prefix":"10.1080","volume":"32","author":[{"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sne\u017eana V.","family":"Jankovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radi\u0161a","family":"Vojinovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sne\u017eana","family":"Luki\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"cit0001","first-page":"543","volume":"8","author":"Dravet C.","year":"1978","journal-title":"Vie Med"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2011.03964.x"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.02994.x"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108741"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00898-1"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17274"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2127089"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2022.05.003"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27837-w"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1550"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2021.147743"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6100"},{"key":"cit0013","unstructured":"Clinical Studies [Internet]. Stoke therapeutics. [Cited 2023 Jan 28]. Available from: https:\/\/www.stoketherapeutics.com\/pipeline\/studies\/"},{"key":"cit0014","unstructured":"Stoke Therapeutics, Inc. An open-label study to investigate the safety and pharmacokinetics of single and multiple ascending doses of antisense oligonucleotide STK-001 in children and adolescents with Dravet syndrome [Internet]. clinicaltrials.gov; 2022 Feb [cited 2023 Jan 24]. Report No.: NCT04442295. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04442295"},{"key":"cit0015","unstructured":"Stoke therapeutics presents data from a combined interim analysis of the phase 1\/2a MONARCH and ADMIRAL Studies of STK-001 in children and adolescents with Dravet syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting - Stoke Therapeutics [Internet]. [Cited 2023 Jan 28]. Available from: https:\/\/investor.stoketherapeutics.com\/news-releases\/news-release-details\/stoke-therapeutics-presents-data-combined-interim-analysis-phase\/"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.05.011"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-022-02001-1"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0112-22.2022"},{"key":"cit0019","volume-title":"American Epilepsy Society Annual Meeting","author":"Giagtzoglou N","year":"2022"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1641"},{"key":"cit0021","unstructured":"Dracaena_DravetSyndromePipelineReview_2022.pdf [Internet]. [Cited 2023 Jan 28]. Available from: https:\/\/static1.squarespace.com\/static\/54589576e4b01c74d3bdbdd3\/t\/639b0e7b09a8286ea8f9ca61\/1671106183307\/Dracaena_DravetSyndromePipelineReview_2022.pdf"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2022.037"},{"key":"cit0023","unstructured":"Encoded therapeutics. ENDEAVOR: a clinical study to evaluate the safety and efficacy of ETX101, an AAV9-delivered gene therapy in infants and children With SCN1A-positive Dravet syndrome [Internet]. clinicaltrials.gov; 2022 Jun [Cited 2023 Jan 26]. Report No.: NCT05419492. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05419492"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2021.08.003"},{"key":"cit0025","volume-title":"Poster No. 3.049, American Epilepsy Society Annual Meeting","author":"Goodchild SJ","year":"2022"},{"key":"cit0026","unstructured":"DIACOMIT_US_PI_2022.pdf [Internet]. [Cited 2023 Jan 28]. Available from: https:\/\/www.diacomit.com\/wp-content\/uploads\/2022\/10\/DIACOMIT_US_PI_2022.pdf"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.980937"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.114238"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106976"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2023.107091"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2022.05.006"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12624"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108994"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17367"},{"key":"cit0035","unstructured":"A study of soticlestat as an add-on therapy in children and young adults with Dravet syndrome - tabular view - clinicalTrials.gov [Internet]. [Cited 2023 Jan 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04940624"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12604"},{"key":"cit0037","unstructured":"Longboard Pharmaceuticals. Randomized, double-blind, placebo-controlled, parallel-group, dose-escalation study to investigate the safety, tolerability, PK, PD, and exploratory efficacy of LP352 in subjects with developmental and epileptic encephalopathies [Internet]. clinicaltrials.gov; 2023 Jan [Cited 2023 Jan 26]. Report No.: NCT05364021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05364021"},{"issue":"18","key":"cit0038","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/WNL.98.18_supplement.1750","volume":"98","author":"Parasrampuria D","year":"2022","journal-title":"Neurology"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12580"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52891-9.00065-8"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13889"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1177\/0192623314551840"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706910"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2023.2193680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T04:38:37Z","timestamp":1702096717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2023.2193680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"alternative-id":["10.1080\/13543784.2023.2193680"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2023.2193680","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}